EcoDrugPlus


Synonyms	NSC-31812 NSC-683531 Sulfathiazole Sulfathiazole (triple sulfa) Sulphathiazole Thiazamide Triple sulfa (sulfathiazole)
Status
Molecule Category	UNKNOWN
ATC	D06BA02 J01EB07
UNII	Y7FKS2XWQH
EPA CompTox	DTXSID8026068

Synonyms

NSC-31812

NSC-683531

Sulfathiazole

Sulfathiazole (triple sulfa)

Sulphathiazole

Thiazamide

Triple sulfa (sulfathiazole)

Status

Molecule Category

UNKNOWN

ATC

D06BA02 J01EB07

UNII

Y7FKS2XWQH

EPA CompTox

DTXSID8026068


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	JNMRHUJNCSQMMB-UHFFFAOYSA-N
Smiles	Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
InChI	InChI=1S/C9H9N3O2S2/c10-7-1-3-8(4-2-7)16(13,14)12-9-11-5-6-15-9/h1-6H,10H2,(H,11,12)

InChI Key

JNMRHUJNCSQMMB-UHFFFAOYSA-N

Smiles

Nc1ccc(S(=O)(=O)Nc2nccs2)cc1

InChI

InChI=1S/C9H9N3O2S2/c10-7-1-3-8(4-2-7)16(13,14)12-9-11-5-6-15-9/h1-6H,10H2,(H,11,12)

Mechanism of Action	Action	Reference
Bacterial dihydropteroate synthase inhibitor	INHIBITOR	PubMed

Mechanism of Action

Action

Reference

Bacterial dihydropteroate synthase inhibitor

INHIBITOR

PubMed

Resources	Reference
ChEBI	9337
ChEMBL	CHEMBL437
DrugBank	DB06147
DrugCentral	2527
FDA SRS	Y7FKS2XWQH
Human Metabolome Database	HMDB0015619
KEGG	C11169
PDB	YTZ
PubChem	5340
SureChEMBL	SCHEMBL94165
ZINC	ZINC000000121458

Resources

Reference

ChEBI

ChEMBL

DrugBank

DrugCentral

FDA SRS

Human Metabolome Database

KEGG

PDB

PubChem

SureChEMBL

ZINC


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

SULFATHIAZOLE

Structure

Pharmacology

Cross References